BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...CAR T and bispecific therapies at ASCO, and both candidates are Amgen’s. CAR T therapy AMG 119...
...T cell immunoglobulin and mucin domain 3 VEGF - Vascular endothelial growth factor Allison Johnson, Staff Writer AMG 119 JNJ-61186372...
BioCentury | May 4, 2018
Targets & Mechanisms

Solid hopes for T cell bispecifics

...cancer (SCLC) mouse models. AMG 757, the BiTE, is in Phase I for relapsed/refractory SCLC. AMG 119...
BioCentury | Jan 12, 2018
Clinical News

Amgen to start its first CAR T trial in 1H18

...CAR) T cell therapy this half. The trial will evaluate a single IV infusion of AMG 119...
...disclose AMG 119's target or details about the trial. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: AMG 119...
...Endpoint: Dose-limiting toxicities (DLTs) Status: Phase I start Milestone: Phase I start (1H18) Elizabeth S. Eaton Amgen Inc. AMG 119...
Items per page:
1 - 3 of 3